Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NFE2L2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NFE2L2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NFE2L2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NFE2L2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NFE2L2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NFE2L2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NFE2L2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NFE2L2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NFE2L2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000759915 | Oral cavity | EOLP | hemostasis | 42/2218 | 222/18723 | 1.40e-03 | 9.58e-03 | 42 |
GO:00149104 | Oral cavity | EOLP | regulation of smooth muscle cell migration | 21/2218 | 89/18723 | 1.40e-03 | 9.58e-03 | 21 |
GO:000863123 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway in response to oxidative stress | 13/2218 | 45/18723 | 1.64e-03 | 1.09e-02 | 13 |
GO:003440511 | Oral cavity | EOLP | response to fluid shear stress | 11/2218 | 35/18723 | 1.74e-03 | 1.14e-02 | 11 |
GO:003043321 | Oral cavity | EOLP | ubiquitin-dependent ERAD pathway | 20/2218 | 85/18723 | 1.87e-03 | 1.21e-02 | 20 |
GO:007124116 | Oral cavity | EOLP | cellular response to inorganic substance | 42/2218 | 226/18723 | 2.00e-03 | 1.28e-02 | 42 |
GO:00148123 | Oral cavity | EOLP | muscle cell migration | 24/2218 | 110/18723 | 2.11e-03 | 1.33e-02 | 24 |
GO:007030121 | Oral cavity | EOLP | cellular response to hydrogen peroxide | 22/2218 | 98/18723 | 2.17e-03 | 1.35e-02 | 22 |
GO:014046721 | Oral cavity | EOLP | integrated stress response signaling | 8/2218 | 22/18723 | 2.64e-03 | 1.59e-02 | 8 |
GO:00435364 | Oral cavity | EOLP | positive regulation of blood vessel endothelial cell migration | 18/2218 | 76/18723 | 2.85e-03 | 1.69e-02 | 18 |
GO:200037923 | Oral cavity | EOLP | positive regulation of reactive oxygen species metabolic process | 18/2218 | 76/18723 | 2.85e-03 | 1.69e-02 | 18 |
GO:003649921 | Oral cavity | EOLP | PERK-mediated unfolded protein response | 7/2218 | 18/18723 | 3.15e-03 | 1.84e-02 | 7 |
GO:0050878110 | Oral cavity | EOLP | regulation of body fluid levels | 63/2218 | 379/18723 | 3.36e-03 | 1.94e-02 | 63 |
GO:190180023 | Oral cavity | EOLP | positive regulation of proteasomal protein catabolic process | 24/2218 | 114/18723 | 3.45e-03 | 1.99e-02 | 24 |
GO:00149094 | Oral cavity | EOLP | smooth muscle cell migration | 21/2218 | 97/18723 | 4.26e-03 | 2.33e-02 | 21 |
GO:199074825 | Oral cavity | EOLP | cellular detoxification | 24/2218 | 116/18723 | 4.36e-03 | 2.38e-02 | 24 |
GO:003461424 | Oral cavity | EOLP | cellular response to reactive oxygen species | 30/2218 | 155/18723 | 4.46e-03 | 2.42e-02 | 30 |
GO:0010226 | Oral cavity | EOLP | response to lithium ion | 8/2218 | 24/18723 | 4.89e-03 | 2.61e-02 | 8 |
GO:190217523 | Oral cavity | EOLP | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 9/2218 | 29/18723 | 4.94e-03 | 2.62e-02 | 9 |
GO:00435344 | Oral cavity | EOLP | blood vessel endothelial cell migration | 33/2218 | 176/18723 | 4.94e-03 | 2.62e-02 | 33 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0522513 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa0501244 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0520844 | Cervix | N_HPV | Chemical carcinogenesis - reactive oxygen species | 32/349 | 223/8465 | 4.82e-10 | 1.87e-08 | 1.47e-08 | 32 |
hsa0541845 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
hsa0414144 | Cervix | N_HPV | Protein processing in endoplasmic reticulum | 21/349 | 174/8465 | 8.84e-06 | 1.09e-04 | 8.55e-05 | 21 |
hsa0541745 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0501254 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0520854 | Cervix | N_HPV | Chemical carcinogenesis - reactive oxygen species | 32/349 | 223/8465 | 4.82e-10 | 1.87e-08 | 1.47e-08 | 32 |
hsa0541855 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFE2L2 | SNV | Missense_Mutation | | c.242N>A | p.Gly81Asp | p.G81D | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
NFE2L2 | SNV | Missense_Mutation | | c.959N>G | p.Ser320Cys | p.S320C | Q16236 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NFE2L2 | SNV | Missense_Mutation | | c.371C>G | p.Ala124Gly | p.A124G | Q16236 | protein_coding | deleterious(0.03) | benign(0.02) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
NFE2L2 | insertion | Frame_Shift_Ins | novel | c.1128_1129insTT | p.Glu377LeufsTer6 | p.E377Lfs*6 | Q16236 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NFE2L2 | insertion | Frame_Shift_Ins | novel | c.1126_1127insTTGTGGTTATAATTTCCCTGATTTGCCATGAGTTTGAACATCTTCCA | p.Ser376PhefsTer22 | p.S376Ffs*22 | Q16236 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NFE2L2 | deletion | Frame_Shift_Del | novel | c.129delN | p.Glu45SerfsTer32 | p.E45Sfs*32 | Q16236 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
NFE2L2 | SNV | Missense_Mutation | novel | c.594G>T | p.Gln198His | p.Q198H | Q16236 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NFE2L2 | SNV | Missense_Mutation | | c.1138G>C | p.Glu380Gln | p.E380Q | Q16236 | protein_coding | deleterious(0.01) | possibly_damaging(0.522) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NFE2L2 | SNV | Missense_Mutation | | c.85G>C | p.Asp29His | p.D29H | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
NFE2L2 | SNV | Missense_Mutation | | c.1544N>C | p.Arg515Thr | p.R515T | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALDICARB | ALDICARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | 3,3'-DIMETHOXYBENZIDINE | CHEMBL398363 | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | LOTEPREDNOL ETABONATE | LOTEPREDNOL ETABONATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BECLOMETHASONE DIPROPIONATE | BECLOMETHASONE DIPROPIONATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PHENOXYCARB | PHENOXYCARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | METHIOCARB | METHIOCARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | JNJ-1661010 | CHEMBL460273 | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | NALED | NALED | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | MORNIFLUMATE | MORNIFLUMATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | RHEIN | RHEIN | |